Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Y H Park; E Senkus-Konefka; S-A Im; G Pentheroudakis; S Saji; S Gupta; H Iwata; M Y Mastura; R Dent; Y-S Lu; Y Yin; B K Smruti; T Toyama; S Malwinder; S C Lee; L-M Tseng; J H Kim; T-Y Kim; K J Suh; F Cardoso; T Yoshino; J-Y Douillard

doi:10.1016/j.annonc.2020.01.008

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Ann Oncol. 2020 Apr;31(4):451-469. doi: 10.1016/j.annonc.2020.01.008. Epub 2020 Jan 16.

Authors

Y H Park¹, E Senkus-Konefka², S-A Im³, G Pentheroudakis⁴, S Saji⁵, S Gupta⁶, H Iwata⁷, M Y Mastura⁸, R Dent⁹, Y-S Lu¹⁰, Y Yin¹¹, B K Smruti¹², T Toyama¹³, S Malwinder¹⁴, S C Lee¹⁵, L-M Tseng¹⁶, J H Kim¹⁷, T-Y Kim³, K J Suh³, F Cardoso¹⁸, T Yoshino¹⁹, J-Y Douillard²⁰

Affiliations

¹ Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address: yhparkhmo@skku.edu.
² Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.
³ Division of Hematology-Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
⁴ Department of Medical Oncology, University of Ioannina, Ioannina, Greece.
⁵ Department of Medical Oncology, Fukushima Medical University, Fukushima, Japan.
⁶ Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, India.
⁷ Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
⁸ Pantai Cancer Institute, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.
⁹ Medical Oncology, National Cancer Center Singapore, Singapore, Singapore.
¹⁰ Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
¹¹ Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
¹² Medical Oncology, Lilavati Hospital and Research Centre and Bombay Hospital Institute of Medical Sciences, Mumbai, India.
¹³ Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
¹⁴ Sri Kota Specialist Medical Centre, Selangor, Malaysia.
¹⁵ Department of Haematology-Oncology, National University, Cancer Institute, Singapore, (NCIS) National University Health System, Singapore, Singapore.
¹⁶ Department of Surgery, Taipei-Veterans General Hospital, Taipei, Taiwan.
¹⁷ Division of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
¹⁸ Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.
¹⁹ Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
²⁰ Chief Medical Officer, ESMO, Lugano, Switzerland.

PMID: 32081575
DOI: 10.1016/j.annonc.2020.01.008

Abstract

In view of the planned new edition of the most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of primary breast cancer published in 2015, it was decided at the ESMO Asia Meeting in November 2018, by both the ESMO and the Korean Society of Medical Oncology (KSMO), to convene a special face-to-face guidelines meeting in 2019 in Seoul. The aim was to adapt the latest ESMO 2019 guidelines to take into account the ethnic and geographical differences associated with the treatment of early breast cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with early breast cancer representing the oncology societies of Korea (KSMO), China (CSCO), India (ISMPO) Japan (JSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices, and the drug availability and reimbursement situations, in the individual participating Asian countries.

Keywords: ESMO guidelines; Pan-Asian; consensus; early breast cancer.

Publication types

Practice Guideline
Research Support, Non-U.S. Gov't

MeSH terms

Asia
Breast Neoplasms* / diagnosis
Breast Neoplasms* / therapy
China
Humans
India
Japan
Malaysia
Medical Oncology
Republic of Korea
Taiwan